Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Ingrid Mayer

8 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Treatment

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment

VICCBRE1390

04/23/2014

A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone-Receptor Positive, HER2-negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease

Treatment

VICCBREP1363

03/21/2014

A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

Treatment

VICCPHI1364

03/07/2014

A Phase Ib, Open-Label Study of Oral BGJ398 in Combination with Oral BYL719 in Adult Patients with Select Advanced Solid Tumors

Treatment

VICCBRE12101

04/04/2013

A Phase Ib Trial of BYL719 (an a-Specific PI3K Inhibitor) in Combination with Endocrine Therapy in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Treatment

VICCBREP12116

03/25/2013

An Open-Label, Phase I/IIa Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Treatment

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer